Similar articles

• [Pharmacokinetics of intravenous methotrexate in children with neoplasms of the hematopoietic system].

  Hermann T, Skibińska L, Szwarc E, Michalewska D. Hermann T, et al. Pol Tyg Lek. 1984 May 21;39(21):713-6. Pol Tyg Lek. 1984. PMID: 6592554 Polish. No abstract available.
• [Results of long-term administration of high-dose methotrexate and its pharmacokinetics in non-Hodgkin's lymphoma in children].

  Sasaki K, Fujimoto T, Shingaki Y, Hara T. Sasaki K, et al. Rinsho Ketsueki. 1983 Feb;24(2):96-103. Rinsho Ketsueki. 1983. PMID: 6655883 Japanese. No abstract available.
• [Massive dose methotrexate with citrovorum factor rescue: MTX-pharmacokinetics, excretion pattern, and techniques for safety administration (author's transl)].

  Sasaki K, Fujimoto T. Sasaki K, et al. Nihon Gan Chiryo Gakkai Shi. 1979 Oct 20;14(6):988-96. Nihon Gan Chiryo Gakkai Shi. 1979. PMID: 317293 Japanese. No abstract available.
• [Methotrexate in pediatric hemato-oncology].

  Bouffet E, Frappaz D. Bouffet E, et al. Pediatrie. 1987;42(4):241-7. Pediatrie. 1987. PMID: 3313265 Review. French. No abstract available.
• Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis.

  Furst DE. Furst DE. J Rheumatol Suppl. 1985 Dec;12 Suppl 12:11-4. J Rheumatol Suppl. 1985. PMID: 3913770 Review.